Medical Oddities: Friends, Family… and Faster Aging?
-
By
-
Teraya Smith
-
March 18, 2026
-
6 min
By
Teraya Smith
March 18, 2026
The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.
August 25, 2026
Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.
August 31, 2026
Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.
August 28, 2026